NO20064579L - Bifenylforbindelser anvendelige som muskariniske receptorantagonister - Google Patents

Bifenylforbindelser anvendelige som muskariniske receptorantagonister

Info

Publication number
NO20064579L
NO20064579L NO20064579A NO20064579A NO20064579L NO 20064579 L NO20064579 L NO 20064579L NO 20064579 A NO20064579 A NO 20064579A NO 20064579 A NO20064579 A NO 20064579A NO 20064579 L NO20064579 L NO 20064579L
Authority
NO
Norway
Prior art keywords
receptor antagonists
muscarinic receptor
compounds useful
compounds
biphenyl compounds
Prior art date
Application number
NO20064579A
Other languages
English (en)
Other versions
NO338941B1 (no
Inventor
Craig Husfeld
Yu-Hua Ji
Li Li
Mathai Mammen
Yongqi Mu
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of NO20064579L publication Critical patent/NO20064579L/no
Publication of NO338941B1 publication Critical patent/NO338941B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Det beskrives forbindelser med formel (I) der a, b, c, d, m, n, p, s, t, W, Ar1, R1, R2, R3, R4, R6, R7 og R8 er som angitt. Forbindelsene med formel (I) er muskariniske receptorantagonister. Det beskrives videre farmasøytisk preparater inneholdende slike forbindelser, fremgangsmåter og mellomprodukter for fremstilling av slike forbindelser og metoder for å anvende forbindelsene for å behandle pulmonære forstyrrelser.
NO20064579A 2004-03-11 2006-10-09 Bifenylforbindelser nyttige som muskariniske reseptorantagonister, fremgangsmåte for fremstilling derav, produkt, farmasøytisk preparat, medikament samt anvendelser NO338941B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55244304P 2004-03-11 2004-03-11
PCT/US2005/007988 WO2005087738A1 (en) 2004-03-11 2005-03-10 Biphenyl compounds useful as muscarinic receptor antagonists

Publications (2)

Publication Number Publication Date
NO20064579L true NO20064579L (no) 2006-11-08
NO338941B1 NO338941B1 (no) 2016-10-31

Family

ID=34963910

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20064579A NO338941B1 (no) 2004-03-11 2006-10-09 Bifenylforbindelser nyttige som muskariniske reseptorantagonister, fremgangsmåte for fremstilling derav, produkt, farmasøytisk preparat, medikament samt anvendelser

Country Status (28)

Country Link
US (22) US7288657B2 (no)
EP (2) EP1930323B1 (no)
JP (1) JP4837653B2 (no)
KR (1) KR101174740B1 (no)
CN (1) CN1930125B (no)
AR (2) AR048032A1 (no)
AT (2) ATE395335T1 (no)
AU (1) AU2005222411B2 (no)
BR (1) BRPI0508622B8 (no)
CA (1) CA2557479C (no)
CY (1) CY1109015T1 (no)
DE (2) DE602005021258D1 (no)
DK (1) DK1723114T3 (no)
ES (2) ES2345640T3 (no)
HK (2) HK1097537A1 (no)
HR (1) HRP20080301T3 (no)
IL (1) IL177359A (no)
MA (1) MA28524B1 (no)
MY (1) MY144482A (no)
NO (1) NO338941B1 (no)
NZ (1) NZ549472A (no)
PL (1) PL1723114T3 (no)
PT (1) PT1723114E (no)
RU (1) RU2366656C2 (no)
SI (1) SI1723114T1 (no)
TW (1) TWI341836B (no)
WO (1) WO2005087738A1 (no)
ZA (1) ZA200607099B (no)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005087736A1 (en) * 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723108A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200538095A (en) * 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
GB0501956D0 (en) * 2005-01-31 2005-03-09 Arrow Internat Nebulizer formulation
JP2008538104A (ja) * 2005-03-10 2008-10-09 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US7479562B2 (en) * 2005-03-10 2009-01-20 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7728144B2 (en) * 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
PL3210981T3 (pl) 2009-04-23 2019-06-28 Theravance Respiratory Company, Llc Związki diamidowe wykazujące działanie jako antagonista receptora muskarynowego i agonista antagonista receptora beta 2 adrenergicznego
JP5651174B2 (ja) * 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ビフェニル化合物の結晶性遊離塩基形
CN102958916B (zh) 2010-07-13 2015-03-25 施万生物制药研发Ip有限责任公司 制备联苯-2-基氨基甲酸的方法
WO2012106382A1 (en) * 2011-01-31 2012-08-09 Genoa Pharmaceuticals, Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9679336B2 (en) * 2011-10-19 2017-06-13 Facebook, Inc. Social ad hoc networking protocol and presentation layer
CN107074816B (zh) * 2015-03-27 2020-07-17 四川海思科制药有限公司 一种杂环衍生物及其制备方法和在医药上的用途
CN107849047B (zh) * 2015-09-28 2021-01-15 四川海思科制药有限公司 一种联苯衍生物及其制备方法和在医药上的用途
CN107849009B (zh) * 2015-10-13 2021-03-02 四川海思科制药有限公司 一种八氢环戊二烯并[c]吡咯衍生物及其制备方法和在医药上的用途
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
US11591323B2 (en) * 2019-03-06 2023-02-28 Barry university Muscarinic agonists as non-steroidal and non-opioid analgesics and methods of use thereof
CN110526859B (zh) * 2019-08-07 2021-03-12 山东百诺医药股份有限公司 一种瑞维那新中间体及其制备方法和瑞维那新的制备方法
CN112694434B (zh) * 2020-12-29 2023-06-16 浙江和泽医药科技股份有限公司 一种雷芬那辛新中间体及其活性亲电砌块和雷芬那辛的新制备方法
WO2023017404A1 (en) * 2021-08-13 2023-02-16 Begum Dr M Sasthaa A device, a compound, for inhalation of an anti-viral agent
WO2023104920A1 (en) 2021-12-09 2023-06-15 Medichem, S.A. Crystalline acetone solvate of revefenacin
CN117263848A (zh) * 2023-09-19 2023-12-22 山东京卫制药有限公司 一种雷芬那辛的吸入喷雾剂

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US747952A (en) * 1903-03-02 1903-12-29 Harry Cauley Dillon Ironing-board.
BR8007911A (pt) 1979-12-06 1981-06-16 Glaxo Group Ltd Inalador aperfeicoado
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
SE8603252L (sv) 1985-07-30 1987-01-31 Glaxo Group Ltd Anordning for att tillfora lekemedel till patienter
US5225183A (en) 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US6006745A (en) 1990-12-21 1999-12-28 Minnesota Mining And Manufacturing Company Device for delivering an aerosol
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
AU2178392A (en) 1991-06-12 1993-01-12 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5337740A (en) 1991-08-01 1994-08-16 New England Pharmaceuticals, Inc. Inhalation devices
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
DK0717987T3 (da) 1991-12-18 2001-11-12 Minnesota Mining & Mfg Suspension-aerosol-formuleringer
HU0004452D0 (no) * 1991-12-18 2001-01-29 Astra Ab
GB9206989D0 (en) * 1992-03-31 1992-05-13 Glaxo Group Ltd Chemical compounds
US5239993A (en) 1992-08-26 1993-08-31 Glaxo Inc. Dosage inhalator providing optimized compound inhalation trajectory
AU7545894A (en) 1993-09-02 1995-03-22 Yamanouchi Pharmaceutical Co., Ltd. Carbamate derivative and medicine containing the same
US5415162A (en) 1994-01-18 1995-05-16 Glaxo Inc. Multi-dose dry powder inhalation device
CA2182568A1 (en) 1994-02-10 1995-08-17 Makoto Takeuchi Novel carbamate derivative and medicinal composition containing the same
US5983956A (en) 1994-10-03 1999-11-16 Astra Aktiebolag Formulation for inhalation
RU2126001C1 (ru) * 1995-01-10 1999-02-10 Самдзин Фармасьютикал Ко., Лтд Производные пиперазина и фармацевтическая композиция на их основе
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles
PL180901B1 (pl) 1995-04-14 2001-04-30 Glaxo Wellcome Inc Inhalator z dozymetrem
US6464979B1 (en) * 1996-09-12 2002-10-15 Aventis Pasteur Limited Chlamydial vaccines and methods of preparation thereof
US6040344A (en) 1996-11-11 2000-03-21 Sepracor Inc. Formoterol process
WO1999016766A1 (fr) 1997-10-01 1999-04-08 Kyowa Hakko Kogyo Co., Ltd. Derives de benzodioxole
CA2323771A1 (en) 1998-03-14 1999-09-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Phthalazinone pde iii/iv inhibitors
IL139087A0 (en) 1998-04-18 2001-11-25 Glaxo Group Ltd Pharmaceutical aerosol formulation
GB9808802D0 (en) 1998-04-24 1998-06-24 Glaxo Group Ltd Pharmaceutical formulations
EP1086066A4 (en) 1998-06-08 2001-08-08 Advanced Medicine Inc MUSCARINIC RECEPTOR ANTAGONISTS
SE9804000D0 (sv) 1998-11-23 1998-11-23 Astra Ab New composition of matter
US6693202B1 (en) * 1999-02-16 2004-02-17 Theravance, Inc. Muscarinic receptor antagonists
EP1169019B1 (en) 1999-04-14 2003-02-26 Glaxo Group Limited Pharmaceutical aerosol formulation
DE19933926A1 (de) 1999-07-20 2001-01-25 Boehringer Ingelheim Pharma Biphenylderivate, ihre Herstellung und ihre Verwendung als Arzneimittel
US6510182B1 (en) * 1999-10-25 2003-01-21 Freesystems Pte. Ltd. Wireless infrared digital audio system
DE60021282T2 (de) * 1999-12-07 2006-05-18 Theravance, Inc., South San Francisco Carbamat-derivate als muscarin-rezeptor antonisten
UA73543C2 (uk) * 1999-12-07 2005-08-15 Тераванс, Інк. Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
UA73965C2 (en) 1999-12-08 2005-10-17 Theravance Inc b2 ADRENERGIC RECEPTOR ANTAGONISTS
EP1345937B1 (en) 2000-12-22 2005-09-28 Almirall Prodesfarma AG Quinuclidine carbamate derivatives and their use as m3 antagonists
US6656694B2 (en) 2001-01-11 2003-12-02 Theravance, Inc. Method for identifying a ligand for a biological substrate
GB0103630D0 (en) 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
EP1366025B1 (en) 2001-03-08 2007-06-27 Glaxo Group Limited Agonists of beta-adrenoreceptors
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
US20030018019A1 (en) 2001-06-23 2003-01-23 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics, corticosteroids and betamimetics
EP1425001B1 (en) 2001-09-14 2008-12-17 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
US6653323B2 (en) 2001-11-13 2003-11-25 Theravance, Inc. Aryl aniline β2 adrenergic receptor agonists
AU2003258507A1 (en) 2002-07-30 2004-02-23 Unilever Plc Abrasive hard surface cleaning compositions
UY27927A1 (es) 2002-08-06 2003-12-31 Glaxo Group Ltd Antagonistas del receptor muscarínico m3 de acetilcolina
PE20040950A1 (es) 2003-02-14 2005-01-01 Theravance Inc DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
JP4851937B2 (ja) 2003-11-21 2012-01-11 セラヴァンス， インコーポレーテッド β２アドレナリン作動性受容体作動薬活性およびムスカリン受容体拮抗薬活性を有する化合物
TW200538095A (en) 2004-03-11 2005-12-01 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) 2004-03-11 2005-09-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7501442B2 (en) 2004-03-11 2009-03-10 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) * 2004-03-11 2011-05-11 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
EP1723113A1 (en) * 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
EP1723108A1 (en) 2004-03-11 2006-11-22 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7456199B2 (en) * 2004-03-11 2008-11-25 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) * 2005-03-10 2010-02-09 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
WO2006099032A1 (en) * 2005-03-10 2006-09-21 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
JP2008538104A (ja) 2005-03-10 2008-10-09 セラヴァンス， インコーポレーテッド ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US7479562B2 (en) * 2005-03-10 2009-01-20 Theravance, Inc. Biphenyl compounds useful as muscarinic receptor antagonists
TW200714587A (en) * 2005-03-10 2007-04-16 Theravance Inc Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) 2005-03-10 2012-09-21 Theravance Inc Crystalline forms of a biphenyl compound
US7728144B2 (en) * 2005-06-13 2010-06-01 Theravance, Inc Biphenyl compounds useful as muscarinic receptor antagonists
US20070029346A1 (en) * 2005-08-03 2007-02-08 Fu-Tian Hung Pneumatic greaser
TW200811105A (en) 2006-04-25 2008-03-01 Theravance Inc Dialkylphenyl compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
WO2007127473A2 (en) * 2006-04-27 2007-11-08 Intezyne Technologies, Inc. Poly (ethylene glycol) containing chemically disparate endgroups
JP5651174B2 (ja) 2009-07-15 2015-01-07 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー ビフェニル化合物の結晶性遊離塩基形
CN102958916B (zh) 2010-07-13 2015-03-25 施万生物制药研发Ip有限责任公司 制备联苯-2-基氨基甲酸的方法

Also Published As

Publication number Publication date
BRPI0508622A (pt) 2007-07-31
US7803812B2 (en) 2010-09-28
NZ549472A (en) 2010-06-25
US20080095708A1 (en) 2008-04-24
US20170204061A1 (en) 2017-07-20
US20050203133A1 (en) 2005-09-15
US7910608B2 (en) 2011-03-22
US20220306579A1 (en) 2022-09-29
US20200290966A1 (en) 2020-09-17
DE602005006757D1 (de) 2008-06-26
KR101174740B1 (ko) 2012-08-17
US8557997B2 (en) 2013-10-15
PT1723114E (pt) 2008-07-17
RU2366656C2 (ru) 2009-09-10
US20100249421A1 (en) 2010-09-30
CN1930125B (zh) 2010-07-21
HK1119672A1 (en) 2009-03-13
HRP20080301T3 (en) 2008-09-30
US9926272B2 (en) 2018-03-27
US20160220551A1 (en) 2016-08-04
US20190359570A1 (en) 2019-11-28
US7491736B2 (en) 2009-02-17
BRPI0508622B1 (pt) 2018-05-22
ES2306125T3 (es) 2008-11-01
US20070292356A1 (en) 2007-12-20
US9283183B2 (en) 2016-03-15
ATE467617T1 (de) 2010-05-15
CA2557479A1 (en) 2005-09-22
AR104444A2 (es) 2017-07-19
US20190047957A1 (en) 2019-02-14
CA2557479C (en) 2013-05-07
US20110319625A1 (en) 2011-12-29
DK1723114T3 (da) 2008-07-28
TWI341836B (en) 2011-05-11
US20120190657A1 (en) 2012-07-26
US8173815B2 (en) 2012-05-08
US8912334B2 (en) 2014-12-16
US20180179161A1 (en) 2018-06-28
EP1723114A1 (en) 2006-11-22
MY144482A (en) 2011-09-30
IL177359A (en) 2012-04-30
PL1723114T3 (pl) 2008-10-31
JP2008532922A (ja) 2008-08-21
CY1109015T1 (el) 2014-07-02
US9452161B2 (en) 2016-09-27
US20070265305A1 (en) 2007-11-15
US7550595B2 (en) 2009-06-23
US8053448B2 (en) 2011-11-08
US10106503B2 (en) 2018-10-23
WO2005087738A1 (en) 2005-09-22
RU2006135927A (ru) 2008-04-20
AU2005222411B2 (en) 2011-04-21
US20080071088A1 (en) 2008-03-20
TW200538438A (en) 2005-12-01
US8034946B2 (en) 2011-10-11
JP4837653B2 (ja) 2011-12-14
US20130172301A1 (en) 2013-07-04
EP1930323B1 (en) 2010-05-12
ATE395335T1 (de) 2008-05-15
US20090226379A1 (en) 2009-09-10
EP1723114B1 (en) 2008-05-14
US10343995B2 (en) 2019-07-09
ZA200607099B (en) 2008-09-25
HK1097537A1 (en) 2007-06-29
US20090018165A1 (en) 2009-01-15
US20070292357A1 (en) 2007-12-20
US7585879B2 (en) 2009-09-08
IL177359A0 (en) 2006-12-10
CN1930125A (zh) 2007-03-14
BRPI0508622B8 (pt) 2021-05-25
MA28524B1 (fr) 2007-04-03
US7521041B2 (en) 2009-04-21
AR048032A1 (es) 2006-03-22
EP1930323A1 (en) 2008-06-11
SI1723114T1 (sl) 2008-08-31
US8273894B2 (en) 2012-09-25
US10570092B2 (en) 2020-02-25
NO338941B1 (no) 2016-10-31
KR20070011370A (ko) 2007-01-24
US20140171397A1 (en) 2014-06-19
US20110130422A1 (en) 2011-06-02
DE602005021258D1 (de) 2010-06-24
US8017783B2 (en) 2011-09-13
US20150164795A1 (en) 2015-06-18
AU2005222411A1 (en) 2005-09-22
US7288657B2 (en) 2007-10-30
ES2345640T3 (es) 2010-09-28
US11247969B2 (en) 2022-02-15

Similar Documents

Publication Publication Date Title
NO20064579L (no) Bifenylforbindelser anvendelige som muskariniske receptorantagonister
DK1716152T3 (da) Kondenserade heterocykliske forbindelser og deres anvendelse som metabotrope receptorantagonister til behandling af gastrointentinde lidelser
ATE463495T1 (de) Oxadiazolylpyrazolopyrimidine als mglur2- antagonisten
NO20063599L (no) Ytterligere heterosykliske forbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
MY143834A (en) Thrombin receptor antagonists
NO20083909L (no) Bisykliske benzimidazolforbindelser, og deres anvendelse som metabotropiske glutamatreseptorforsterkere
NO20062677L (no) Benzyleteraminforbindelser anvendbare som CCR-5-antagonister
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
TW200714587A (en) Biphenyl compounds useful as muscarinic receptor antagonists
NO20064065L (no) Diaminopyrimidiner som P2X3 og P2X2/3 antagonister
NO20071108L (no) Nye 4-benzylidenpiperidinderivater
CY1108880T1 (el) Παραγωγα καρβοξαμιδιου ως ανταγωνιστες μουσκαρινικου υποδοχεα
NO20073663L (no) Tiazol-4-karboksamid-derivater som mGluR5 antagonister
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
ATE496620T1 (de) 1h-benzo(f)indazol-5-yl-derivate als selektive glucocorticoid-rezeptor-modulatoren
NO20071660L (no) Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
IS8377A (is) Arýlindenópyridín og arýlindenópyrimidín og notkun þeirra sem mótlyf A2A viðtaka adenósíns
NO20092689L (no) Quinuclidinolderivater som muskarin reseptorantagonister
NO20063597L (no) Acetylinske piperazinforbindelser og deres anvendelse som metabotrofiske glutamatreseptorantagonister
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
TW200624432A (en) Imidazo [1,2-a] pyridine compounds, compositions, uses and methods related thereto
EA200600061A1 (ru) Бензамиды 4-(аминометил) пиперидина как 5нт-антагонисты
NO20075477L (no) Tetrahydro-pyridoazepin-8-one og beslektede forbindelser for behandling av schizofreni

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US

CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: THERAVANCE BIOPHARMA R&D IP, US